학술논문

Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer.
Document Type
Article
Source
International Journal of Gynecological Cancer; Apr2022, Vol. 32 Issue 4, p502-507, 6p
Subject
Language
ISSN
1048891X